Business context and reporting period
The supplied filing is PerkinElmer, Inc.’s Form 10-K for the 52-week fiscal year ended December 30, 2012, filed February 26, 2013. It is not a filing under the name Revvity, Inc., and it reports a full fiscal year rather than only 2012 Q4; the filing text does not provide a clear basis for reconciling that metadata mismatch. PerkinElmer operated in Human Health and Environmental Health, serving diagnostics, research, environmental, industrial, and laboratory-services markets.
Financial performance and position
- Revenue: $2.115 billion, up 10% from $1.919 billion in fiscal 2011. Management attributed approximately 7% growth to acquisitions and approximately 2% decline to foreign exchange. Human Health revenue rose 18% to $1.044 billion; Environmental Health revenue rose 4% to $1.071 billion.
- Profit and margins: Gross profit was $963.2 million and gross margin was 45.5%, up from 44.2%. Operating income was $98.5 million, versus $91.1 million; operating margin was approximately 4.7%. Continuing-operations income was $68.4 million, or $0.60 diluted EPS, compared with $1.2 million, or $0.01, in 2011. Net income was $69.9 million, or $0.61 diluted EPS.
- Cash flow: Cash from continuing operations was $153.6 million, down from $234.0 million. Capital expenditures were $42.4 million. Cash and cash equivalents increased to $171.4 million from $142.3 million.
- Debt and liquidity: Year-end debt carrying value was approximately $940.6 million, including $258.0 million drawn on the revolving credit facility; cash was $171.4 million. The company reported $429.7 million of additional revolver availability and compliance with applicable covenants. Current assets were $971.8 million and current liabilities were $581.1 million.
- Capital returns: The annual declared dividend was $0.28 per share. No open-market program repurchases were made during fiscal 2012; after year-end, approximately 2.6 million shares were repurchased for $89.0 million through February 22, 2013.
Material changes versus the prior comparable period
- Revenue growth was led by Human Health, including the contribution from the 2011 Caliper acquisition, and by growth in laboratory services. Industrial-market demand weakened, and pharmaceutical customers’ lower research spending and declining radioactive-reagent demand were offsets.
- Human Health operating income fell 26% to $73.7 million, while Environmental Health operating income declined 2% to $97.3 million. Results included a $74.2 million non-cash impairment charge for trade names after a brand-strategy realignment.
- Interest and other expense increased to $48.0 million from $26.8 million, primarily reflecting higher debt and interest expense associated with financing the Caliper acquisition.
- The continuing-operations tax result shifted from a $63.2 million provision in 2011 to a $17.9 million benefit in 2012. The prior-year provision included $79.7 million related to planned repatriation of foreign earnings, making reported year-over-year earnings comparisons unusually affected by tax items.
- Operating cash flow declined by $80.4 million, with working capital use and timing of tax, restructuring, and compensation payments among the cited factors. Investing cash use fell sharply from 2011’s acquisition-heavy year.
Outlook, commentary, risks, and unusual items
- Management expected fiscal 2013 capital expenditures to be similar to fiscal 2012 and planned to continue significant R&D investment. It forecast annual restructuring savings exceeding $11 million beginning in fiscal 2014; immediate savings were expected to approximately offset realignment costs.
- Management cited continued opportunity in disease screening, research tools, laboratory services, and regulated environmental and food-safety testing. It also noted exposure to weaker industrial demand and reduced pharmaceutical R&D spending. No specific revenue or earnings guidance was provided in the supplied filing text.
- Fiscal 2012 included $25.1 million of restructuring and contract-termination charges. Restructuring plans involved workforce reductions, facility actions, and a shared-services transition; approximately $27.8 million of related liabilities remained at year-end.
- Fiscal Q4 revenue was $572.9 million, but operating results were a loss of $30.8 million and net loss was $15.9 million. The quarter included the $74.2 million trade-name impairment and $31.8 million of pension and postretirement mark-to-market expense.
- Haoyuan was acquired in November 2012 for $38.0 million cash, subject to purchase-price adjustments and up to $30.0 million additional contingent consideration. Its post-acquisition revenue and results were described as minimal.
- Key risks include substantial debt and refinancing needs, variable-rate exposure, foreign currency and international-market exposure, acquisition integration and contingent consideration, goodwill and intangible-asset valuation, regulatory and product-liability exposure, supply constraints, and uncertain demand and government funding.
- The company disclosed an ongoing Enzo patent and commercial-practices lawsuit. Management said it was contesting the case and did not expect a material adverse effect, while acknowledging uncertainty. Environmental remediation liabilities accrued were $6.1 million.
Most important facts for investors to verify
- Confirm the issuer and period: this source identifies PerkinElmer, Inc. and fiscal 2012 ended December 30, 2012, not Revvity, Inc. or a standalone Q4 filing.
- Assess how much of the 10% revenue increase was organic, given acquisition contribution, currency effects, and deferred-revenue adjustments on acquired businesses.
- Separate underlying operating performance from the $74.2 million impairment, pension mark-to-market costs, restructuring charges, and unusually favorable 2012 tax result.
- Review debt maturities, especially the $150 million notes due 2015 and revolving-facility borrowing, along with cash availability, covenants, and planned post-year-end repurchases.
- Track whether restructuring savings materialize as planned and whether the trade-name realignment or acquisition integration leads to further impairment or costs.
- Monitor the Enzo litigation, environmental exposures, pension funding requirements, and the final purchase-price allocation and earnout obligations for Haoyuan.